Healius Future Growth

Future criteria checks 3/6

Healius's revenue is forecast to decline at 4.2% per annum while its annual earnings are expected to grow at 85.8% per year. EPS is expected to grow by 94.5% per annum. Return on equity is forecast to be 3.5% in 3 years.

Key information

85.8%

Earnings growth rate

94.5%

EPS growth rate

Healthcare earnings growth	26.3%
Revenue growth rate	-4.2%
Future return on equity	3.5%
Analyst coverage	Good
Last updated	15 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

CHIA:HLS - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2027	1,470	36	259	304	6
6/30/2026	1,401	26	250	288	7
6/30/2025	1,644	166	255	304	6
6/30/2024	1,746	-636	203	267	N/A
12/31/2023	1,692	-984	217	284	N/A
9/30/2023	1,699	-682	237	309	N/A
6/30/2023	1,707	-380	257	333	N/A
12/31/2022	1,839	35	313	407	N/A
9/30/2022	2,064	164	403	497	N/A
6/30/2022	2,289	292	493	587	N/A
12/31/2021	2,292	226	549	624	N/A
9/30/2021	2,103	146	506	575	N/A
6/30/2021	1,914	66	464	526	N/A
3/31/2021	1,802	75	460	512	N/A
12/31/2020	1,690	83	456	497	N/A
9/30/2020	1,630	83	395	452	N/A
6/30/2020	1,570	83	333	407	N/A
12/31/2019	1,502	110	99	233	N/A
9/30/2019	1,534	83	49	180	N/A
6/30/2019	1,566	57	-2	128	N/A
3/31/2019	1,785	29	23	140	N/A
12/31/2018	1,752	2	48	153	N/A
9/30/2018	1,728	3	74	177	N/A
6/30/2018	1,705	4	99	202	N/A
3/31/2018	1,694	-256	N/A	215	N/A
12/31/2017	1,683	-516	N/A	227	N/A
9/30/2017	1,671	-516	N/A	220	N/A
6/30/2017	1,659	-517	N/A	212	N/A
3/31/2017	1,648	-260	N/A	219	N/A
12/31/2016	1,637	-3	N/A	227	N/A
9/30/2016	1,639	18	N/A	256	N/A
6/30/2016	1,642	38	N/A	285	N/A
12/31/2015	1,595	126	N/A	270	N/A
9/30/2015	1,587	121	N/A	255	N/A
6/30/2015	1,580	117	N/A	239	N/A
3/31/2015	1,596	127	N/A	256	N/A
12/31/2014	1,572	118	N/A	271	N/A
9/30/2014	1,548	116	N/A	266	N/A
6/30/2014	1,524	115	N/A	261	N/A
3/31/2014	1,501	134	N/A	256	N/A
12/31/2013	1,478	131	N/A	243	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HLS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: HLS is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: HLS is expected to become profitable in the next 3 years.

Revenue vs Market: HLS's revenue is expected to decline over the next 3 years (-4.2% per year).

High Growth Revenue: HLS's revenue is forecast to decline over the next 3 years (-4.2% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HLS's Return on Equity is forecast to be low in 3 years time (3.5%).

Healius Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Healius Limited Decides Not to Provide Earnings Guidance for the Second Half of 2021

Recent updates

Affinity Equity Partners (Australia) Pty Limited entered into a binding agreement to acquire Lumus Imaging from Healius Limited (ASX:HLS) for enterprise value of AUD 965 million.

Full year 2024 earnings released: AU$0.96 loss per share (vs AU$0.67 loss in FY 2023)

Healius Limited, Annual General Meeting, Nov 15, 2024

Full year 2024 earnings released

TPG Capital, PEP Reportedly Still Competing for Healius Lumus Imaging

Final Bids Reportedly Expected for Healius

Healius Limited Announces Step Down of Ravi Jeyaraj as Non-Executive Director, Effective 2 August 2024

Macquarie Unit Reportedly in Healius Race

Healius Limited to Report Fiscal Year 2024 Results on Aug 21, 2024

Sonic in the Running for Healius Imaging Business

Private Equity Reportedly Eyes Healius Diagnostic Imaging Unit

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

Interim Non-Executive Independent Chair recently bought AU$81k worth of stock

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings released

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

High number of new directors

Independent Non Executive Chairman recently bought AU$103k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold AU$660k worth of stock

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought AU$86k worth of stock

Non Executive & Independent Director recently bought AU$70k worth of stock

Full year 2022 earnings released: EPS: AU$0.50 (vs AU$0.11 in FY 2021)

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Healius Limited, Annual General Meeting, Oct 20, 2022

Healius Reportedly Launches Day Surgery Sale Process

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Healius Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Healius Reportedly Seeks X-Ray Factor in Day Surgeries Sale Plan

Healius Limited Announces Appointment of John Mattick as Non-Executive Director

Upcoming dividend of AU$0.10 per share

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Healius Limited Announces Ordinary Fully Paid Dividend for the Period of Six Months December 31, 2021, Payable April 15, 2022

Healius Limited to Report First Half, 2022 Results on Feb 23, 2022

Healius Limited (ASX:HLS) acquired Agilex Biolabs Pty Ltd.

Healius Limited (ASX:HLS) entered into an agreement to acquire Agilex Biolabs Pty Ltd for approximately AUD 300 million.

MD, CEO & Director recently sold AU$713k worth of stock

Upcoming dividend of AU$0.068 per share

Full year 2021 earnings released: EPS AU$0.11 (vs AU$0.12 in FY 2020)

Healius Limited (ASX:HLS) acquired Axis Diagnostic Holdings Pty Limited.

Healius Reportedly to Sale Day Surgeries

Healius Limited Decides Not to Provide Earnings Guidance for the Second Half of 2021

Healius Limited Appoints Kate McKenzie as A Non-Executive Director Effective from 25 February 2021

New 90-day high: AU$4.16

Healius Limited(ASX:HLS) dropped from S&P/ASX 100 Index

New 90-day high: AU$3.90

BGH Capital completed the acqusition of Primary Care Business of Healius Ltd from Healius Limited (ASX:HLS) for AUD485 million.

Independent Non Executive Director recently bought AU$53k worth of stock

New 90-day high: AU$3.77

Healius Limited Announces Retirement of Arlene Tansey as Non-Executive Director

New 90-day high: AU$3.46

Healius Limited to Report Fiscal Year 2021 Results on Aug 20, 2021

Full year earnings released - EPS AU$0.12

New 90-day high - AU$3.40

Earnings released

New 90-day high - AU$3.20

Earnings and Revenue Growth Forecasts